Impact of the COVID-19 Pandemic on Community Antibiotic Prescribing and Stewardship: A Qualitative Interview Study with General Practitioners in England
Abstract
:1. Introduction
2. Results
2.1. Fluctuations in Antibiotic Prescribing during COVID-19
“Right at the beginning, when COVID first struck, (…) we were treating a lot of chest infections virtually which sounds and goes against everything that we’ve ever been trained to do but we were told we absolutely mustn’t spread COVID, therefore we must keep our distance, that was when PPE was in very short supply. And talking to my colleagues about it, we certainly were prescribing more antibiotics.”(GP02 October 2020)
“As the pandemic has moved on, we’ve gone a little bit more back to normal, I suppose, being more strict, in that we would expect patients to come in if there is a need for an antibiotic (…) it’s [antibiotic prescribing] probably gone back down to a more normal level.”(GP14 May 2021)
“If people meet the number of symptoms threshold that’s set in the [local] guidance, we would just prescribe for them. Most UTIs have generally been dealt with remotely anyway (…) that’s probably never really changed.”(GP12 May 2021)
“Skin infections, because the patient can now send photos of their skin lesion, COVID or no COVID that was happening anyway. Those are quite easy to diagnose remotely.”(GP17 June 2021)
2.2. Changing Ways of Working and Consulting
“I do feel that we probably have prescribed more than we normally would, because of the, especially at the beginning-in March, April, May, the lack of face-to-face consultations, or moving everything online. (…) if someone said they’d got a sore ear, and you can’t look at the ear, then you’re more likely to prescribe something, more likely than not, antibiotics. So that’s just one example of why I think we probably have “overprescribed” antibiotics more than usual.”(GP10 November 2020)
“What we absolutely need to do, as clinicians, is get our hands on the patients. It feels very wrong prescribing without actually listening to somebody’s chest. (…) so this is March, April, to really cover ourselves and cover the patient and make sure we’d covered every eventuality (…) we would be prescribing more readily than we would have before.”(GP02 October 2020)
“…we’re probably spending more time safety-netting than we used to because we haven’t laid our eyes on [patients] necessarily. So it’s more difficult to satisfy ourselves as clinicians that they don’t need antibiotics just based on the history. (…) Whereas in the past you just look at their ear and get all the information (…) Now you’re having to ask 20 questions to get the same information.”(GP06 November 2020)
“If you’ve looked in their ear, looked in their throat, listened to their chest, (…) and you can go through all the negative findings and say, look this is why I think it’s a viral infection. That conversation is a little bit more difficult if you haven’t seen them, and then they get that impression that, well you’re guessing at what’s going on.”(GP18 June 2021)
“…the number of face-to-face consultations has definitely increased from the first wave. (…) …we are examining patients face-to-face when they need to be examined, like their ears and their throat and their chest etc., there should be far fewer so called inappropriate antibiotic prescribing…”(GP10 April 2021)
“Perhaps the fact that we’ve got the hot hub with the respiratory symptoms also helps us sort of, use that as a technique. (…) in a lot of situations we are able to say that we think that you need to be seen for that in which case to go to the hot hub. That kind of extra barrier, it does help us to reduce our antibiotic prescribing for respiratory symptoms and have those conversations around that and what’s normal, what to do if things get worse and so on.”(GP11 November 2020)
2.3. Changing Patient Presentations and Workloads
“At the beginning, I would probably say we prescribed a lot less because we had so few contacts. People just weren’t contacting us for a start. I’d say once contact increased, then we probably prescribed more because we didn’t want to bring people in. Now most people are coming in, it’s probably reduced again.”(GP15 May 2021)
“I have hardly seen any children at all since March which is a huge change as well. (…) I think a lot of it is because the majority of their infections are self-limiting illnesses (…) Also lots of the coughs, colds, fevers were being seen either in the COVID hubs or having COVID swabs and just staying at home, and so for that reason they didn’t really need to see a GP.”(GP14 December 2020)
“…our local guidelines on the treatment of COVID was, if the symptoms didn’t settle, then you would prescribe doxycycline so that was being prescribed.”(GP02 October 2020)
“People have generally become more aware of infections and the way they spread and general things that they can do to try to avoid spreading of the infection, simple hygiene and so on. But I don’t necessarily think that people have become more aware of antibiotics as such because obviously this is a viral pandemic and it’s not a bacterial thing. I don’t think that antibiotic stewardship has been particularly high on the media agenda. This is not really coming across in the news to people that that’s an important thing to consider.”(GP09 November 2020)
“Whereas previously trying to get hold of an appointment was difficult and therefore patient problems either self-resolved or they sought advice from elsewhere, for example seen a pharmacist, now they know they can just send in an e-Consult and then it’s done, so we’re getting patients presenting far, far earlier on…”(GP17 June 2021)
“…lots of our patients don’t want to go into [town] to the COVID hubs. It’s a 45 min journey so they just don’t want to do it, so they do put us under quite a lot of pressure, I don’t want to go that far, can’t you just prescribe for me…”(GP14 December 2020)
2.4. Changing Engagement with AMS Strategies
“We had one meeting with a CCG pharmacist, (…) that would have been December and probably the next one was due in March or April and didn’t happen. And in the meantime, our entire lives have been consumed with COVID planning and getting through the work.”(GP06 November 2020)
2.5. Shifting Priorities
“At the moment, [AMS] is not a priority. We’re overwhelmed with work and we’ve not got enough staff… And to do things proactively just now where they’re not directly impacting on our day to day work is really difficult to do. There are so many other priorities that we’ve got to try and keep the services running, and I suspect a lot of practices feel the same, that they’re struggling to keep services going, deliver the vaccine clinics, and deal with the unmet needs. And where something is not as immediate as that (…) there isn’t the capacity to do things… that don’t have that priority just now. And I’m afraid antibiotic prescribing is one of them. As is a whole lot of other prescribing to be honest with you.”(GP08 May 2021)
“We don’t have any plans as a practice as such at the moment but we tend to respond very well to the [CCG] Medicines Optimisation Team’s strategies that they send out every now and then. So they run a prescribing quality scheme every year, which has actually been deferred this year because of COVID (…) there’s a possibility it won’t restart till next April but that tends to be the main driver for us in terms of affecting our prescribing habits.”(GP09 May 2021)
“Starting with telephone and video consultations opens up a much more, a much smoother pathway for doctors to start thinking about, and the [Healthcare Assistant] led step path after that so, i.e., we can have a quick conversation, take the history, take the concerns, take the ideas, and then tell people to come in and see someone, see an HCA for the necessary observations and tests.”(GP11 November 2020)
3. Discussion
3.1. Limitations
3.2. Implications
4. Methods
4.1. Study Participants
4.2. Data Collection
4.3. Data Analysis
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- World Health Organization. Global Action Plan on AMR; World Health Organization: Geneva, Switzerland; Available online: https://www.who.int/publications/i/item/9789241509763 (accessed on 29 October 2021).
- Department of Health and Social Care. UK 5-Year Action Plan for Antimicrobial Resistance 2019 to London: Department of Health and Social Care. Available online: https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-resistance-2019-to-2024 (accessed on 29 October 2021).
- Public Health England. English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report 2019 to 2020. Available online: https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report (accessed on 29 October 2021).
- Karami, Z.; Knoop, B.T.; Dofferhoff, A.S.M.; Blaauw, M.J.T.; Janssen, N.A.; van Apeldoorn, M.; Kerckhoffs, A.P.M.; van de Maat, J.S.; Hoogerwerf, J.J.; Oever, J.T. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: Results from a multicentre retrospective cohort study in The Netherlands. Infect. Dis. 2021, 53, 102–110. [Google Scholar] [CrossRef]
- Rawson, T.M.; Moore, L.; Zhu, N.; Ranganathan, N.; Skolimowska, K.; Gilchrist, M.; Satta, G.; Cooke, G.; Holmes, A. Bacterial and fungal coinfection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin. Infect. Dis. 2020, 71, 2459–2468. [Google Scholar] [CrossRef]
- Townsend, L.; Hughes, G.; Kerr, C.; Kelly, M.; O’Connor, R.; Sweeney, E.; Doyle, C.; O’Riordan, R.; Martin-Loeches, I.; Bergin, C.; et al. Bacterial pneumonia coinfection and antimicrobial therapy duration in SARS-CoV-2 (COVID-19) infection. JAC Antimicrob. Resist. 2020, 2, dlaa071. [Google Scholar] [CrossRef]
- Vaughn, V.M.; Gandhi, T.N.; Petty, L.A.; Patel, P.K.; Prescott, H.C.; Malani, A.N.; Ratz, D.; McLaughlin, E.; Chopra, V.; Flanders, S.A. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): A multi-hospital cohort study. Clin. Infect. Dis. 2021, 72, e533–e541. [Google Scholar] [CrossRef]
- Cong, W.; Poudel, A.N.; Alhusein, N.; Wang, H.; Yao, G.; Lambert, H. Antimicrobial use in COVID-19 patients in the first phase of the SARS-CoV-2 pandemic: A scoping review. Antibiotics 2021, 10, 745. [Google Scholar] [CrossRef] [PubMed]
- Ashiru-Oredope, D.; Kerr, F.; Hughes, S.; Urch, J.; Lanzman, M.; Yau, T.; Cockburn, A.; Patel, R.; Sheikh, A.; Gormley, C.; et al. Assessing the impact of COVID-19 on antimicrobial stewardship activities/programs in the United Kingdom. Antibiotics 2021, 10, 110. [Google Scholar] [CrossRef]
- Miranda, C.; Silva, V.; Capita, R.; Alonso-Calleja, C.; Igrejas, G.; Poeta, P. Implications of antibiotics use during the COVID-19 pandemic: Present and future. J. Antimicrob. Chemother. 2020, 75, 3413–3416. [Google Scholar] [CrossRef]
- Khor, W.P.; Olaoye, O.; D’Arcy, N.; Krockow, E.M.; Elshenawy, R.A.; Rutter, V.; Ashiru-Oredope, D. The need for ongoing antimicrobial stewardship during the COVID-19 pandemic and actionable recommendations. Antibiotics 2020, 9, 904. [Google Scholar] [CrossRef]
- Mazdeyasna, H.; Nori, P.; Patel, P.; Doll, M.; Godbout, E.; Lee, K.; Noda, A.J.; Bearman, G.; Stevens, M.P. Antimicrobial Stewardship at the core of COVID-19 response efforts: Implications for sustaining and building programs. Curr. Infect. Dis. Rep. 2020, 22, 23. [Google Scholar] [CrossRef]
- Monnet, D.L.; Harbarth, S. Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance? Eurosurveillance 2020, 25, 2001886. [Google Scholar] [CrossRef]
- Subramanya, S.H.; Czyż, D.M.; Acharya, K.P.; Humphreys, H. The potential impact of the COVID-19 pandemic on antimicrobial resistance and antibiotic stewardship. Virusdisease 2021, 32, 330–337. [Google Scholar] [CrossRef]
- Rawson, T.M.; Ming, D.; Ahmad, R.; Moore, L.S.P.; Holmes, A.H. Antimicrobial use, drug-resistant infections and COVID-19. Nat. Rev. Microbiol. 2020, 18, 409–410. [Google Scholar] [CrossRef] [PubMed]
- Rawson, T.M.; Moore, L.S.P.; Castro-Sanchez, E.; Charani, E.; Davies, F.; Satta, G.; Ellington, M.J.; Holmes, A.H. COVID-19 and the potential long-term impact on antimicrobial resistance. J. Antimicrob. Chemother. 2020, 75, 1681–1684. [Google Scholar] [CrossRef]
- Rodríguez-Baño, J.; Rossolini, G.M.; Schultsz, C.; Tacconelli, E.; Murthy, S.; Ohmagari, N.; Holmes, A.; Bachmann, T.; Goossens, H.; Canton, R.; et al. Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance. Trans. R. Soc. Trop. Med. Hyg. 2021, 115, 1122–1129. [Google Scholar] [CrossRef] [PubMed]
- Armitage, R.; Nellums, L.B. Antibiotic prescribing in general practice during COVID-19. Lancet Infect. Dis. 2021, 21, e144. [Google Scholar] [CrossRef]
- Hussain, A.Z.; Paudyal, V.; Hadi, M.A. Impact of the COVID-19 pandemic on the prescribing patterns of first-line antibiotics in english primary care: A longitudinal analysis of national prescribing dataset. Antibiotics 2021, 10, 591. [Google Scholar] [CrossRef] [PubMed]
- Rezel-Potts, E.; L’Esperance, V.; Gulliford, M.C. Antimicrobial stewardship in the UK during the COVID-19 pandemic: A population-based cohort study and interrupted time-series analysis. Br. J. Gen. Pract. 2021, 71, e331–e338. [Google Scholar] [CrossRef] [PubMed]
- Andrews, A.; Budd, E.L.; Hendrick, A.; Ashiru-Oredope, D.; Beech, E.; Hopkins, S.; Gerver, S.; Muller-Pebody, B. Surveillance of antibacterial usage during the COVID-19 pandemic in England. Antibiotics 2021, 10, 841. [Google Scholar] [CrossRef]
- Zhu, N.J.; McLeod, M.; McNulty, C.A.M.; Lecky, D.M.; Holmes, A.H.; Ahmad, R. Trends in antibiotic prescribing in out-of-hours primary care in England from January 2016 to June 2020 to understand behaviours during the first wave of COVID-19. Antibiotics 2021, 10, 32. [Google Scholar] [CrossRef] [PubMed]
- Zhu, N.; Aylin, P.; Rawson, T.; Gilchrist, M.; Majeed, A.; Holmes, A. Investigating the impact of COVID-19 on primary care antibiotic prescribing in North West London across two epidemic waves. Clin. Microbiol. Infect. 2021, 27, 762–768. [Google Scholar] [CrossRef]
- Malcolm, W.; Seaton, R.A.; Haddock, G.; Baxter, L.; Thirlwell, S.; Russell, P.; Cooper, L.; Thomson, A.; Sneddon, J. Impact of the COVID-19 pandemic on community antibiotic prescribing in Scotland. JAC Antimicrob. Resist. 2020, 2, dlaa105. [Google Scholar] [CrossRef]
- Girvin, B.; Hsia, Y.; Turner, W. Antimicrobial stewardship in Northern Ireland during COVID-19. Prescriber 2021, 32, 15–20. [Google Scholar] [CrossRef]
- Van de Pol, A.C.; Boeijen, J.A.; Venekamp, R.P.; Platteel, T.; Damoiseaux, R.A.; Kortekaas, M.F.; van der Velden, A.W. Impact of the COVID-19 pandemic on antibiotic prescribing for common infections in The Netherlands: A primary care-based observational cohort study. Antibiotics 2021, 10, 196. [Google Scholar] [CrossRef] [PubMed]
- Peñalva, G.; Benavente, R.S.; Pérez-Moreno, M.A.; Pérez-Pacheco, M.D.; Pérez-Milena, A.; Murcia, J.; Cisneros, J.M. Effect of the coronavirus disease 2019 pandemic on antibiotic use in primary care. Clin. Microbiol. Infect. 2021, 27, 1058–1060. [Google Scholar] [CrossRef] [PubMed]
- Silva, T.M.; Estrela, M.; Gomes, E.R.; Piñeiro-Lamas, M.; Figueiras, A.; Roque, F.; Herdeiro, M.T. The impact of the COVID-19 pandemic on antibiotic prescribing trends in outpatient care: A nationwide, quasi-experimental approach. Antibiotics 2021, 10, 1040. [Google Scholar] [CrossRef]
- Gillies, M.B.; Burgner, D.P.; Ivancic, L.; Nassar, N.; Miller, J.E.; Sullivan, S.G.; Todd, I.M.; Pearson, S.A.; Schaffer, A.L.; Zoega, H. Changes in antibiotic prescribing following COVID-19 restrictions: Lessons for post-pandemic antibiotic stewardship. Br. J. Clin. Pharmacol. 2021, 2021, 1–9. [Google Scholar] [CrossRef]
- Centor, R.M.; Witherspoon, J.M.; Dalton, H.P.; Brody, C.E.; Link, K. The diagnosis of strep throat in adults in the emergency room. Med. Decis. Mak. 1981, 1, 239–246. [Google Scholar] [CrossRef] [PubMed]
- Little, P.; Moore, M.; Hobbs, F.D.R.; Mant, D.; McNulty, C.; Williamson, I.; Cheng, E.; Stuart, B.; Kelly, J.; Barnett, J.; et al. PRImary care Streptococcal Management (PRISM) study: Identifying clinical variables associated with Lancefield group A β-haemolytic streptococci and Lancefield non-Group A streptococcal throat infections from two cohorts of patients presenting with an acute sore throat. BMJ Open 2013, 3, e003943. [Google Scholar]
- The National Institute for Health and Care Ecvellence (NICE). COVID-19 Rapid Guideline: Managing COVID-19. 2021. Available online: https://www.nice.org.uk/guidance/ng191 (accessed on 29 October 2021).
- Butler, C.C.; Dorward, J.; Yu, L.-M.; Gbinigie, O.; Hayward, G.; Saville, B.R.; Van Hecke, O.; Berry, N.; Detry, M.; Saunders, C.; et al. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): A randomised, controlled, open-label, adaptive platform trial. Lancet 2021, 397, 1063–1074. [Google Scholar] [CrossRef]
- Butler, C.C.; Yu, L.-M.; Dorward, J.; Gbinigie, O.; Hayward, G.; Saville, B.R.; Van Hecke, O.; Berry, N.; Detry, M.A.; Saunders, C.; et al. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): A randomised, controlled, open-label, adaptive platform trial. Lancet Respir. Med. 2021, 9, 1010–1020. [Google Scholar] [CrossRef]
- De Lusignan, S.; Joy, M.; Sherlock, J.; Tripathy, M.; van Hecke, O.; Gbinigie, K.; Williams, J.; Butler, C.; Hobbs, F.R. PRINCIPLE trial demonstrates scope for in-pandemic improvement in primary care antibiotic stewardship: A retrospective sentinel network cohort study. medRxiv 2021. [Google Scholar] [CrossRef]
- Zhu, N.; Rawson, T.M.; Mookerjee, S.; Price, J.R.; Davies, F.; Otter, J.; Aylin, P.; Hope, R.; Gilchrist, M.; Shersing, Y.; et al. Changing patterns of bloodstream infections in the community and acute care across two COVID-19 epidemic waves: A retrospective analysis using data linkage. Clin. Infect. Dis 2021, ciab869. [Google Scholar] [CrossRef]
- Murphy, M.; Scott, L.J.; Salisbury, C.; Turner, A.; Scott, A.; Denholm, R.; Lewis, R.; Iyer, G.; Macleod, J.; Horwood, J. Implementation of remote consulting in UK primary care following the COVID-19 pandemic: A mixed-methods longitudinal study. Br. J. Gen. Pract. 2021, 71, e166–e177. [Google Scholar] [CrossRef] [PubMed]
- Wanat, M.; Hoste, M.; Gobat, N.; Anastasaki, M.; Boehmer, F.; Chlabicz, S.; Colliers, A.; Farrell, K.; Karkana, M.N.; Kinsman, J.; et al. Transformation of primary care during the COVID-19 pandemic: Experiences of healthcare professionals in eight European countries. Br. J. Gen. Pract. 2021, 71, e634–e642. [Google Scholar] [CrossRef] [PubMed]
- Han, S.M.; Greenfield, G.; Majeed, A.; Hayhoe, B. Impact of remote consultations on antibiotic prescribing in primary health care: Systematic review. J. Med. Internet. Res. 2020, 22, e23482. [Google Scholar] [CrossRef]
- Hobbs, F.D.R.; Bankhead, C.; Mukhtar, T.; Stevens, S.; Perera-Salazar, R.; Holt, T.; Salisbury, C. Clinical workload in UK primary care: A retrospective analysis of 100 million consultations in England, 2007. Lancet 2016, 387, 2323–2330. [Google Scholar] [CrossRef] [Green Version]
- Croxson, C.H.; Ashdown, H.F.; Hobbs, F.R. GPs’ perceptions of workload in England: A qualitative interview study. Br. J. Gen. Pract. 2017, 67, e138–e147. [Google Scholar] [CrossRef] [Green Version]
- Borek, A.J.; Anthierens, S.; Allison, R.; McNulty, C.A.M.; Lecky, D.M.; Costelloe, C.; Holmes, A.; Butler, C.C.; Walker, A.S.; Tonkin-Crine, S. How did a quality premium financial incentive influence antibiotic prescribing in primary care? Views of clinical commissioning group and general practice professionals. J. Antimicrob. Chemother. 2020, 75, 2681–2688. [Google Scholar] [CrossRef]
- Thornton, H.V.; Khalid, T.; Hay, A.D. Point-of-care testing for respiratory infections during and after C.OVID-19. Br. J. Gen. Pract. 2020, 70, 574–575. [Google Scholar] [CrossRef]
- Pink, I.; Raupach, D.; Fuge, J.; Vonberg, R.-P.; Hoeper, M.M.; Welte, T.; Rademacher, J. C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19. Infection 2021, 49, 935–943. [Google Scholar] [CrossRef]
- O’Brien, B.C.; Harris, I.B.; Beckman, T.J.; Reed, D.A.; Cook, D.A. Standards for reporting qualitative research: A synthesis of recommendations. Acad. Med. 2014, 89, 1245–1251. [Google Scholar] [CrossRef] [PubMed]
- STEP-UP Study: Improving the Uptake and Sustainability of Effective Interventions to Promote Prudent Antibiotic Use in Primary Care. Available online: https://www.expmedndm.ox.ac.uk/step-up (accessed on 29 October 2021).
- Grossoehme, D.; Lipstein, E. Analyzing longitudinal qualitative data: The application of trajectory and recurrent cross-sectional approaches. BMC Res. Notes 2016, 9, 136. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Braun, V.; Clarke, V. Using thematic analysis in psychology. Qual. Res. Psychol. 2006, 3, 77–101. [Google Scholar] [CrossRef] [Green Version]
AMS Strategy | Summary of Views |
---|---|
Communication strategies to explain prescribing decisions | There were mixed views: Some participants described no change in their communication with patients during the pandemic and remote consultations. Others described that moving to remote consultations made them more focused on detailed history-taking and safety-netting due to the lack of physical examination, and more focused on discussing patient concerns, expectations and understandings of normal/concerning symptoms. |
Delayed/back-up prescriptions | There were mixed views: Some participants reported no change in their use of delayed/back-up prescriptions compared to pre-pandemic (e.g., whether and when they used them, or not used them). Some participants reported using delayed/back-up prescriptions less often, in favour of prescribing immediate antibiotics. Others reported using more delayed/back-up prescriptions during the pandemic as a safety net (especially with limited options to see the patient) or to limit re-consultations. Participants described shifting to fully electronic prescribing (before and some since the pandemic); few perceived electronically sent delayed/back-up prescriptions to be more difficult for patients to understand (e.g., rather than a post-dated paper prescription). |
Point-of-care C-reactive protein (CRP) testing | Participants reported not being able to use the point-of-care testing equipment due to the lack of, and limited, face-to-face contact. Some thought that it could/might be useful for face-to-face consultations, e.g., when they become safer and more frequent again. Some speculated how point-of-care CRP testing could be implemented in the future, e.g., in pharmacies, by triaging patients to have the test and by non-GP clinicians. |
Written patient information leaflets | Most participants reported an increased sharing of patient information due to being able to electronically send or text message links to patient information leaflets/websites to patients, and becoming more used to this system function. Some reported not giving out (printed) information leaflets due to the lack of/limited in-person contact. |
Guidelines | Participants reported following prescribing guidelines as a strategy to ensure appropriate antibiotic prescribing, and many reported that this remained unchanged during the pandemic. Some referred to following COVID-19 guidelines in relation to deciding about antibiotics for patients with (suspected) COVID-19. |
Clinical scores or templates (e.g., Centor [30], FeverPAIN [31]) | Some reported using and adapting clinical scores/templates for new ways of consulting during the pandemic, e.g.,: Using algorithms as part of the triage process (e.g., to identify potential infections, sepsis or COVID-19). Using FeverPAIN and/or Centor in remote consultations as part of an assessment with slight adaptations, e.g., instead of making observations in a physical examination, they would ask patients about these (e.g., fever, swollen glands), ask to see their throat in a video or picture or ask a relative to look at the patient’s throat and describe it. |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Borek, A.J.; Maitland, K.; McLeod, M.; Campbell, A.; Hayhoe, B.; Butler, C.C.; Morrell, L.; Roope, L.S.J.; Holmes, A.; Walker, A.S.; et al. Impact of the COVID-19 Pandemic on Community Antibiotic Prescribing and Stewardship: A Qualitative Interview Study with General Practitioners in England. Antibiotics 2021, 10, 1531. https://doi.org/10.3390/antibiotics10121531
Borek AJ, Maitland K, McLeod M, Campbell A, Hayhoe B, Butler CC, Morrell L, Roope LSJ, Holmes A, Walker AS, et al. Impact of the COVID-19 Pandemic on Community Antibiotic Prescribing and Stewardship: A Qualitative Interview Study with General Practitioners in England. Antibiotics. 2021; 10(12):1531. https://doi.org/10.3390/antibiotics10121531
Chicago/Turabian StyleBorek, Aleksandra J., Katherine Maitland, Monsey McLeod, Anne Campbell, Benedict Hayhoe, Christopher C. Butler, Liz Morrell, Laurence S. J. Roope, Alison Holmes, Ann Sarah Walker, and et al. 2021. "Impact of the COVID-19 Pandemic on Community Antibiotic Prescribing and Stewardship: A Qualitative Interview Study with General Practitioners in England" Antibiotics 10, no. 12: 1531. https://doi.org/10.3390/antibiotics10121531